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Abstract
α-Synuclein is a small protein that has special relevance for understanding Parkinson disease and
related disorders. Not only is α-synuclein found in Lewy bodies characteristic of Parkinson disease,
but also mutations in the gene for α-synuclein can cause an inherited form of Parkinson disease and
expression of normal α-synuclein can increase the risk of developing Parkinson disease in sporadic,
or non-familial, cases. Both sporadic and familial Parkinson disease are characterized by substantial
loss of several groups of neurons, including the dopaminergic cells of the substantia nigra that are
the target of most current symptomatic therapies. Therefore, it is predicted that α-synuclein,
especially in its mutant forms or under conditions where its expression levels are increased, is a
toxic protein in the sense that it is associated with an increased rate of neuronal cell death. This
review will discuss the experimental contexts in which α-synuclein has been demonstrated to be
toxic. I will also outline what is known about the mechanisms by which α-synuclein triggers
neuronal damage, and identify some of the current gaps in our knowledge about this subject. Finally,
the therapeutic implications of toxicity of α-synuclein will be discussed.
All neurodegenerative diseases share the common phe-
nomenon that neurons, usually relatively specific groups,
are lost progressively as the disease develops. In some
cases, we can provide partial relief for patients by treating
some of their symptoms. However, because we don't
understand the underling mechanisms of why neurons
die, degeneration continues inexorably and old symp-
toms often become unresponsive while new ones arrive.
At the end of the disease process, we are left with only a
few clues about what might have happened based on what
we can glean from the pathology of the disease using post
mortem samples. In general, the root cause of neurodegen-
eration remains obscure although rare genetic variants are
helpful in that we can be certain that an inherited muta-
tion acts as the trigger for disease in that specific family.
Here, I will discuss cell loss related to Parkinson disease
(PD) in the context of one protein, α-synuclein, that has
several links to the disorder. In doing so, I will outline
what we know about the ways in which a protein can lead
to cell death. Before doing so, it is worth discussing what
PD is, and what it isn't.
Cell death in PD
It is very commonly said that PD is the second most com-
mon neurodegenerative disease and results from a loss of
dopamine neurons. The first fact is dull and the second
tells only part of the story. It is true that PD patients have
a substantial loss of dopamine in the striatum resulting
from a relatively selective loss of dopaminergic projection
neurons in the substantia nigra pars compacta. Both bio-
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chemical measures and imaging modalities suggest that at
least a 70% decrease in striatal dopamine occurs before
the onset of clinical parkinsonism and progresses over
time [1]. These estimates of the extent of striatal
dopamine depletion, combined with the observation that
the majority of dopaminergic neurons are lost by the end
of the disease process, imply that there is substantial cell
death throughout the PD disease process. It is not possible
to show this directly, but measurements of nigral cell
numbers in neurologically normal people and in non-
human primates reveal a slow progressive loss of
dopamine neurons with age [2]. In this view, parkinson-
ism is an accelerated, but still slow, cell death phenotype
that would normally be seen with aging [3].
However, while there is relative vulnerability of dopamin-
ergic neurons in the substantia nigra [4], not all dopamine
cells are affected in PD. For example, although dopamin-
ergic neurons in the ventral tegmental area that project to
the nucleus accumbens do degenerate [5], compared to
the dopaminergic neurons in the substantia nigra pars
compacta these cells are relatively spared [6,7].
Furthermore, not all affected neurons in PD are dopamin-
ergic. Non-motor symptoms are a serious problem for
many PD patients and are often untreated by replacement
therapy with L-DOPA (3,4-dihydroxy-L-phenylalanine)
[8]. A good example of non-dopaminergic cells that
degenerate in PD is the cholinergic neurons in the dorsal
vagal nucleus [9]. It has been suggested that involvement
of non-nigral regions underlies the complex clinical pic-
ture in PD [10]. Therefore, although there is some specifi-
city to cell death in PD, there is no absolute selectivity for
any specific neurotransmitter group or anatomic region. It
is also important to note that loss of nigral neurons occurs
in diverse pathological situations [4] and that on its own,
nigral cell loss defines the clinical term parkinsonism, not
Parkinson disease.
This distinction is also important when discussing the
other major pathological event in PD that appears along-
side cell death, the formation of Lewy bodies and Lewy
neurites. Lewy bodies are intracellular deposits of proteins
and lipids [11] that were traditionally stained with eosin
but now are more sensitively recognized by antibodies to
specific marker proteins [12]. Using electron microscopy,
Lewy bodies are fibrillar structures with a recognizable
core and halo [13]. The range of Lewy pathology is now
recognized as encompassing many regions of the diseased
brain [14] including, for example, the olfactory bulb,
raphe nucleus, locus coeruleus and the basal nucleus of
Meynert. Additionally, some reports suggest that the nigra
is not the first place where Lewy bodies form [15]. How
this relates to the extent of cell loss in each region is not
well defined. Lewy bodies are also seen in dementia with
Lewy bodies (DLB, also known as Diffuse Lewy body Dis-
ease or DLBD), suggesting that PD and DLBD are related
to one another by shared pathology and maybe by shared
etiology.
Therefore, PD is a disease where substantial cell loss in the
nigra occurs alongside the formation of Lewy bodies. Nei-
ther cell loss nor Lewy bodies is absolutely specific for PD
but both are required for a diagnosis of PD under current
definitions [16]. This review will focus on cell death, but
it is important to understand a little more about the most
commonly used marker for Lewy bodies; α-synuclein.
α-Synuclein is a marker of the PD process
The first member of the family of proteins for which α-
synuclein is named was cloned from the neuromuscular
junction of the electric eel [17]. Antibodies against that
protein labeled both synapses and nuclei, leading to the
naming of synuclein. A related protein was cloned from
zebra finch as a protein upregulated during the process of
song learning, a period of enormous synaptic plasticity
[18]. In humans, there are three synuclein family mem-
bers (α-,β-,γ-) and all synuclein genes are relatively well
conserved both within and between species [19]. The
synuclein genes are specific to the vertebrate lineage in
that neither single cell organisms (including yeast) nor
invertebrates (Drosophila melanogaster, Caenorhabditis ele-
gans) have any apparent synuclein homologue. Addition-
ally, primate α-synuclein sequences differ from other
vertebrate synucleins by a substitution of Alanine for a
Threonine at position 53 [20]. These two interesting facts
about the evolutionary relationships in the synuclein fam-
ily are important for understanding some of the experi-
mental systems where synuclein has been explored.
The normal function of α-synuclein is poorly understood.
Although it is expressed at high levels in the brain, rela-
tively specifically within neurons, it is also found in other
tissues, e.g., hematopoietic cells [21,22]. α-Synuclein can
bind to lipids [23] and, in neurons, is associated with pre-
synaptic vesicles [24,25] and the plasma membrane, pos-
sibly via lipid rafts [26]. The association of α-synuclein
with vesicles is modulated by synaptic activity where the
protein dissociates from vesicles after electrical stimula-
tion of the neuron and only slowly re-associates [27].
However, α-synuclein knockout mice show only subtle
abnormalities in neurotransmission [28-30], suggesting
that α-synuclein plays a non-essential function at the syn-
apse. There is some evidence that such a modulatory role
may be more important under conditions where reactive
oxygen species or nitric oxide are present [31,32],
although the mechanism(s) are not yet fully defined.
In the normal brain, α-synuclein immunostaining reveals
a diffuse pattern of reactivity throughout the neuropil thatMolecular Neurodegeneration 2009, 4:9 http://www.molecularneurodegeneration.com/content/4/1/9
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would be consistent with a predominantly synaptic local-
ization [25]. However, in PD brains, α-synuclein antibod-
ies strongly stain Lewy bodies [33] and Lewy neurites [34].
Because of this sensitivity, α-synuclein staining is now
more commonly used than eosin or ubiquitin staining for
these structures. Biochemical analyses have shown that α-
synuclein is a major protein component of Lewy bodies
and may be part of the fibrillar structure of these structures
[35]. The deposited, pathological forms of α-synuclein are
aggregated and show lower solubility than the normal
protein [36] and may be modified post-translationally by
truncation, nitration, ubiquitylation and phosphoryla-
tion [37-40].
Therefore, α-synuclein protein deposition into Lewy bod-
ies is a marker of the PD disease state. However, because
we require Lewy bodies for a PD diagnosis this isn't an
especially strong argument for involvement of α-synu-
clein in the disease process. It is also important to note
that, although we cannot determine if Lewy bodies previ-
ously formed in the cells that eventually died, the individ-
ual neurons where Lewy bodies are found are the ones
that have survived the disease process (though they still
may be dysfunctional). Very recently, it has been shown
that Lewy bodies form in functional dopaminergic neu-
rons grafted in to brains of people with PD as a therapeu-
tic intervention [41,42], although this is not always seen
[43]. These were embryonic cells that remained appar-
ently healthy and were functional after grafting, which
suggests that there is the environment of the PD brain pre-
disposes even young cells to form Lewy bodies.
In summary, the available evidence identifies α-synuclein
as a marker of the PD/DLB process but do not prove that
it has a causal role. The evidence that it does comes from
a variety of human genetic studies.
α-Synuclein can cause PD
A key discovery in understanding PD was the report that
an A53T mutation in the α-synuclein gene was causal for
dominantly inherited disease [44]. This was the first clear
report that a Mendelian gene could be a cause of PD,
which to that point had been thought of as a non-genetic
disease. It is interesting that the first mutation found was
A53T, i.e. a reversion of the human Alanine to the ances-
tral Threonine found in rodents and many other species.
Since then, two other point mutations, A30P [45] and
E46K [46], have been reported in different families. It is
also important that while many cases are reported to have
a phenotype of 'PD', in fact several patients in the A53T
and E46K [46] families have a more diffuse involvement
of synuclein deposition [47,48] and clinical features that
presumably result from this degree of involvement of
non-dopaminergic systems [49].
A second group of important cases have multiplications of
the normal wild type allele of SNCA, the gene that
encodes for the α-synuclein protein. Cases with SNCA
duplication have a brainstem-predominant PD pheno-
type [50], while cases with a triplication have a Lewy body
disease that again involves several brain regions [51,52].
Measurements of protein levels in triplication show the
predicted doubling of α-synuclein in blood as well as
increased levels and deposition of the protein in the cere-
bral cortex where Lewy bodies are found [21]. Therefore,
even without sequence variants, α-synuclein dosage can
be causal for Lewy body disease.
A third piece of genetic evidence comes from the reports
common variants around the α-synuclein gene are associ-
ated with lifetime risk of sporadic PD. Both the promoter
region, specifically the Rep1 polymorphic repeat [53], and
polymorphisms towards the 3' end of the gene are associ-
ated with PD [54]. Although it is not known specifically
how these risk variants influence lifetime incidence of PD,
it seems likely that they increase α-synuclein protein levels
in the brain.
Collectively, the human genetic data strongly support a
causal role for α-synuclein in PD/DLBD. Whether Lewy
bodies are causal or consequential is less clear, but they do
support the idea that α-synuclein represents an important
link between sporadic and inherited PD. The various lines
of evidence identify α-synuclein as a potentially toxic pro-
tein, fulfilling the requirements of a causative agent in PD
[55]. The question now is how, and in what context, is α-
synuclein toxic, and can we do anything about it?
Where and when is α-synuclein toxic?
Given that cell loss is a major event in human PD, com-
bined with the evidence that α-synuclein plays a causal
role in disease, it is reasonable to infer that α-synuclein is
toxic to human neurons. The time course is likely to be
protracted, with the most likely explanation that there is
asynchronous cell death that results in a slow depletion of
the populations of relatively vulnerable neurons. How-
ever, it is not possible to watch cells die in the human
brain and so we have to turn to experimental models to
confirm or refute the idea that α-synuclein is toxic.
Yeast models are probably the simplest system used to
show that expression of human α-synuclein evokes toxic
events. In growing and stationary phase cultures,
increased expression of α-synuclein limits cell growth [56-
65]. These experiments are extraordinarily useful in defin-
ing pathways that underpin the toxic effects of the protein.
α-Synuclein toxicity has also been demonstrated in Dro-
sophila, where dopaminergic neuron cell loss has been
reported [66-73], although this result is a little controver-
sial [74] and the effects are modest. The worm C. elegans
can also be used to show that α-synuclein can damage
dopamine neurons in an intact, in vivo, setting [75-80].
What links these three model systems is that they all show
a detrimental effect of expression of α-synuclein in organ-Molecular Neurodegeneration 2009, 4:9 http://www.molecularneurodegeneration.com/content/4/1/9
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isms where the protein is not normally present. One read-
ing of this data is that, at least in terms of toxicity
occurring over days to weeks, the normal function of the
protein is probably not relevant.
A situation where α-synuclein is normally present is in
mammalian cell culture models. Two commonly used sys-
tems are primary neurons, including dopaminergic cul-
tures of the ventral midbrain, or neuroblastoma derived
cell lines. Experiments showing the most substantial
effects of α-synuclein include those where the protein is
transiently expressed, e.g. from viral vectors [81-86], or
expression is controlled from an inducible promoter sys-
tem [87-89], although some authors have reported a lack
of toxicity in similar circumstances [90]. In midbrain cul-
tures, toxicity is higher for dopamine neurons than other
cells [81], which may be relevant to the relative vulnera-
bility of nigral neurons in PD. Some experiments show
nicely that the difference between wild type and mutant
protein is really a matter of dose and that at increasing
expression levels, the normal protein becomes as toxic as
the dominant mutants [89].
Although potentially useful in for understanding mecha-
nisms, these cell-based models are taken out of their in
vivo context and tend to show cell loss over a few days,
compared to the predicted years of progress in the disease.
A more intact approach is to express α-synuclein using
transgenic technology in various parts of the mouse CNS.
Some of these models show toxicity, particularly in the
spinal cord, but nigral cell loss is absent or modest [91-
97]. Several models do show accumulation and insolubil-
ity of α-synuclein [e.g., [36,91,93,98]], although whether
true Lewy bodies are formed is uncertain. Therefore, most
mouse models reported to date are better for understand-
ing  α-synuclein deposition than frank cellular toxicity.
Why this is the case is unclear, but it is interesting that
crossing transgenic models with mouse α-synuclein
knockouts exacerbates phenotypes [99-101], suggesting
that the presence of the murine protein limits damage in
some undefined way. The lack of an ideal PD mouse
model that more completely captures the human pheno-
type limits our current studies of α-synuclein toxicity.
Though a goal worth pursuing, creation of such an ideal
mouse model may be very challenging given the limita-
tions of mouse lifespan and differences in physiology
between mice and humans.
An alternate approach to traditional transgenics is to use
viral vectors to deliver α-synuclein directly to the substan-
tia nigra in mice [102], rats [103-106] or non-human pri-
mates [107-109]. In these approaches, a significant cell
loss is noted along with deposition of α-synuclein pro-
tein. The extent of cell loss is less dramatic than in human
PD and behavioral effects are similarly modest. However,
the critical observation here is that α-synuclein can induce
toxicity in vivo using vertebrate organisms, with a time
course of several weeks, allowing for some dissection of
mechanism.
Taken together, all of this evidence suggests that α-synu-
clein can induce toxicity in a variety of contexts, from sim-
ple organisms to dopamine neurons in the primate
substantia nigra. It is less clear whether all of these situa-
tions are directly relevant to the human disease, where cell
loss is probably more protracted, but as a practical matter
such models at least afford an opportunity to examine
mechanism(s) by which α-synuclein triggers neuronal
death.
Why is α-synuclein toxic?
Some of the above model systems have been used to
probe the mechanism(s) by which α-synuclein causes cell
death. These can generally be sorted into aspects of the
protein itself effects of the protein to the biological system
(see figure 1). Appendix 1 highlights some of the key
observations related to this critical question.
Aspects of protein chemistry of  -synuclein and toxicity
α-Synuclein has a strong tendency to self-associate in vitro
[110,111], and so a prime candidate for the underlying
driving force for toxicity is the formation of aggregated
species. One of the important questions about this idea is
which species are present in cells/tissues. Oligomeric spe-
cies can be isolated from cells [112-114] and from human
[21] and mouse (both wild type and α-synuclein trans-
genic) brain [115]. In both cells and brain, oligomers are
particularly found in membrane-enriched fractions
[112,115], suggesting a possible influence of the lipid
environment on oligomer formation. Higher molecular
weight forms have also been found in some models [116],
especially after oxidative stress [117] or exposure to
inflammatory triggers in mice [100]. Deposited α-synu-
clein immunoreactivity has been seen in transgenic [91-
97] or viral models [102-109]. However, the observation
of aggregated α-synuclein by and of itself does not prove
that aggregation is important; as discussed for Lewy bod-
ies, all this proves is that deposition occurs, not that it is
causal.
Some recent studies have attempted to answer this ques-
tion, mainly using cell-based approaches. For example,
some oligomeric forms of α-synuclein trigger calcium
entry and toxicity in SY5Y cells [118]. Interestingly, differ-
ent species show differential toxicity, suggesting that not
all oligomers are created equal. However, the nature of
this experiment is to add α-synuclein to the outside of the
cell, which may or may not be relevant to the pathophys-
iological situation. As α-synuclein is intracellular, it seems
more likely that the protein would form aggregate insideMolecular Neurodegeneration 2009, 4:9 http://www.molecularneurodegeneration.com/content/4/1/9
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Events in α-synuclein toxicity Figure 1
Events in α-synuclein toxicity. The central panel shows the major pathway for protein aggregation. Monomeric α-synuclein 
is natively unfolded in solution but can also bind to membranes in an α-helical form. It seems likely that these two species exist 
in equilibrium within the cell, although this is unproven. From in vitro work, it is clear that unfolded monomer can aggregate 
first into small oligomeric species that can be stabilized by β-sheet-like interactions and then into higher molecular weight 
insoluble fibrils. In a cellular context, there is some evidence that the presence of lipids can promote oligomer formation: α-
synuclein can also form annular, pore-like structures that interact with membranes. The deposition of α-synuclein into patho-
logical structures such as Lewy bodies is probably a late event that occurs in some neurons. On the left hand side are some of 
the known modifiers of this process. Electrical activity in neurons changes the association of α-synuclein with vesicles and may 
also stimulate polo-like kinase 2 (PLK2), which has been shown to phosphorylate α-synuclein at Ser129. Other kinases have 
also been proposed to be involved. As well as phosphorylation, truncation through proteases such as calpains, and nitration, 
probably through nitric oxide (NO) or other reactive nitrogen species that are present during inflammation, all modify synu-
clein such that it has a higher tendency to aggregate. The addition of ubiquitin (shown as a black spot) to Lewy bodies is prob-
ably a secondary process to deposition. On the right are some of the proposed cellular targets for α-synuclein mediated 
toxicity, which include (from top to bottom) ER-golgi transport, synaptic vesicles, mitochondria and lysosomes and other pro-
teolytic machinery. In each of these cases, it is proposed that α-synuclein has detrimental effects, listed below each arrow, 
although at this time it is not clear if any of these are either necessary or sufficient for toxicity in neurons.
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cells. The presence of fibrils in Lewy bodies would support
this contention. However, α-synuclein can end up in the
extracellular media [119] and it is possible that the condi-
tions for aggregation might be more suitable in a milieu
free of cells. The relevance of extracellular α-synuclein is
an important question, raised also by the observation of
Lewy bodies in grafted neurons [41,42] and the attendant
hypothesis of 'host to graft transmission'.
Some studies have attempted to address whether intracel-
lular aggregates of α-synuclein contribute to toxicity. For
example, several imaging techniques shown that, in the
context of a living cell, α-synuclein can form small oli-
gomers, likely in an antiparallel configuration [114,120]
and such oligomers can be associated with cell toxicity.
These approaches have been used to show that overex-
pression of heat shock proteins (Hsps) can mitigate both
oligomer formation and toxicity [114,120,121]. In vivo,
Hsps can prevent toxic effects of α-synuclein in yeast [59]
and in flies [67]. Whether these studies constitute formal
proof that aggregation is required for toxicity is unclear as
there are other theoretical interpretations of the data. For
example, a formal possibility is that monomeric α-synu-
clein is toxic and, thus, any protein binding the protein
directly could limit toxicity. It should be stated that the
mechanism(s) by which monomers of α-synuclein could
be toxic are relatively unexplored but, equally, there is an
absence of proof that aggregation is absolutely required
for toxicity. Alternatively, Hsps could be limiting a detri-
mental event downstream of the initial aggregation and
thus may neither represent evidence for or against the role
of aggregation in α-synuclein toxicity. Interestingly, Hsp
expression in the fly model decreases neuronal toxicity
without any change in the number of α-synuclein positive
inclusions [67].
Overall, these considerations show that α-synuclein is
capable of protein aggregation and can be deposited into
inclusion bodies of various forms in vivo, but that there is
insufficient evidence that aggregation or deposition is
either necessary or sufficient for toxicity. In fact, several
lines of evidence show that toxicity can be dissociated
from deposition, including; the observation in cells of
toxicity without deposition in some models [81]; differen-
tial effects on toxicity and inclusions of various manipula-
tions of α-synuclein in fly models [66,67]; and deposition
of α-synuclein without clear toxic effects in some mouse
models [e.g., [36]]. A key challenge for the field, therefore,
is to understand whether protein aggregation is at all rele-
vant for the toxic effects of α-synuclein. One way to poten-
tially address this is to isolate various aggregated species of
the protein and to express them within a neuron. This
might be extraordinarily difficult from a technical stand-
point and there is always possibility that the small aggre-
gates would seed larger ones may confound
interpretation. Another potential approach would be to
develop reagents that limit the biological availability of
specific aggregated species and use these to probe which
agents are toxic in intact cells. As an example, recom-
binant single chain Fv antibody fragments against aggre-
gated  α-synuclein have been described [122,123] that
might be helpful.
α-Synuclein has many additional properties as well as the
tendency to aggregate. Some of the post-translational
modifications that have been reported have also been
explored as possible mediators of toxicity. For example,
antibodies against α-synuclein phosphorylated at Ser129
are very good at identifying Lewy pathology in the human
brain [38], suggesting either that Ser129 phosphorylation
is a causal event for deposition or represents a common
modification of the protein after it is deposited. Several
groups have therefore made versions of α-synuclein that
cannot be modified at this residue (S129A) or pseudo-
phosphorylation mimics (S129D, S129E) and deter-
mined the toxic effects of expression. In Drosophila mod-
els, S129A is less toxic but has an increased tendency to
form inclusion bodies compared to wild type protein
[66]. The S129D phosphomimic has the opposite effect,
i.e. increased toxicity but fewer inclusions. In contrast,
similar experiments using viral overexpression in rats
show the opposite result, namely that S129A greatly
increases the toxic effects of expression [124]. In mamma-
lian cell culture, S129A has a diminished tendency to
form inclusion bodies [125].
At first glance, these results seem to suggest that the behav-
ior of α-synuclein as it relates to toxicity is opposite in
mammals compared to invertebrates where, it is impor-
tant to note, the protein is not normally present. However,
interpretation is complicated by several considerations.
First, the expression levels of α-synuclein are critical for
toxicity, which is shown by the human case where a differ-
ence in protein levels is 2-fold in the triplication cases and
1.5-fold in the duplication cases. Second, recent data sug-
gests that the phosphomimic S129D/E α-synuclein vari-
ants have different biophysical properties compared to
authentically phosphorylated wild type protein [126].
Overall, these considerations raise some important caveats
about comparison of properties of α-synuclein in terms of
concentration-dependent behaviors of the protein such as
aggregation and toxicity.
One alternate approach to understand α-synuclein phos-
phorylation is to identify the kinase that mediates the
phosphotransfer event. Casein kinase II and GRK2/5 have
been shown to phosphorylate α-synuclein in vitro or in
cells and work in yeast [64] and flies [66] respectively
shows that they are at least active in vivo. More recently,Molecular Neurodegeneration 2009, 4:9 http://www.molecularneurodegeneration.com/content/4/1/9
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the polo-like kinase family, specifically PLK2, have been
shown to be active both in vitro and in vivo in generating
pS129 α-synuclein [127]. What is interesting about PLK2
is that it is known to respond to neuronal activity [128],
suggesting a possible link between neuronal phenotype
and α-synuclein toxicity. However, it is not yet known in
PLK2 inhibitors or gene knockout will limit the toxic
effects of α-synuclein in vivo. Such experiments are feasi-
ble in several species as PLK2 homologues are present in
mice and flies, and there is at least one polo kinase in
yeast.
There are a number of other modifications of α-synuclein
that have been reported and some of these are found more
often in pathological circumstances than under normal
conditions, such as nitration or truncation. Truncation of
α-synuclein is associated with a higher tendency for aggre-
gation [129-131]. Transgenic mice expressing truncated α-
synuclein have substantial cell loss [101] although in at
least one line, this is a developmental and not degenera-
tive phenotype [132]. Again, because the window for tox-
icity is quite narrow, comparison between different lines
is difficult. One question that arises for truncation is
where such species are generated. α-Synuclein is predom-
inantly degraded by lysosomal pathways [133,134],
including chaperone-mediated autophagy [135], and the
lysosomal cathepsins are important in proteolysis. There-
fore, some truncated species are found in the lysosomes
and it seems unlikely that they would cause damage to the
cell. However, α-synuclein is also a substrate for cytoplas-
mic calpains [136-139], which are therefore more likely to
generate cytoplasmic toxic truncated species. Some detail
is therefore needed to prove which truncated species
mediate toxicity, if any of them in fact do.
Oxidative stress, including the neurotransmitter
dopamine, has been linked to increased α-synuclein
aggregation [89,140]. Dopamine itself may contribute to
the toxic effects of α-synuclein in vitro [89], although such
a mechanism cannot explain why non-dopaminergic neu-
rons die early in the disease process. α-Synuclein expres-
sion can enhance sensitivity to oxidative and nitrative
stressors [141,142], although it can also be protective in
some situations [143]. In most of these situations, the role
of aggregation is unclear.
In summary, α-synuclein has properties, including the
potential for aggregation and post-translational modifica-
tions, which may influence its toxic effects. Whether these
are required for toxicity is unclear, and some results still
need to be resolved, for example for the work on S129
phosphorylation. However, there is a larger question,
which is: what effects synuclein has on neurons that are
responsible for its toxic effects?
Mediators of  -synuclein toxicity in biological systems
Some of the relevant data from cellular systems has been
reviewed previously [144] and will be discussed here in
the context of examples across multiple models.
Presumably, α-synuclein might interact with other bio-
molecules to mediate toxicity. Because α-synuclein can
associate with lipids, membranes are one possible target.
In vitro,  α-synuclein can form pore-like structures
[145,146], and annular rings of synuclein have been iso-
lated from the brains of patients with multiple system
atrophy, a synucleinopathy [147]. Cells expressing α-
synuclein have increased cation permeability [148] and
vesicles prepared from cultured cells or isolated from the
adrenal medulla show leakage of catecholamines [149].
These events may be consistent with the formation of
non-specific pores or similar structures at the plasma
membrane or at a vesicle surface.
Because α-synuclein binds synaptic vesicles, it is possible
that synaptic transmission would be directly or indirectly
a target of synuclein toxicity. One example of this comes
from work showing that A30P α-synuclein alters exocyto-
sis of catecholamine containing vesicles in primary cells
and in chromaffin cells [150]. The effect here is probably
at a late stage of the exocytosis, before vesicle membrane
fusion [150].
Further evidence for an effect of α-synuclein on vesicle
function that may mediate toxicity comes from suppressor
screens in yeast [63]. In the same organism, such defects
can be localized to a block in endoplasmic reticulum
(ER)-golgi vesicular trafficking [151]. Supporting this
idea, there is evidence of ER stress [87] and golgi fragmen-
tation [152] in mammalian cell systems.
Overexpression of Rab1, a GTPase that influences vesicle
dynamics, was able to at least partially rescue the toxic
effects of α-synuclein in yeast, worms and in mammalian
cells [151]. Therefore, some of the toxic effects of α-synu-
clein that are conserved across species involve damage to
vesicular transport, which might express itself as damage
to presynaptic vesicle release in a neuron.
There are also suggestions that other membranous
organelles are affected by α-synuclein, including mito-
chondria [87,88,153]. Recent data suggests that a portion
of α-synuclein can localize to mitochondria, at least under
some conditions [154-157]. Supporting this are observa-
tions that α-synuclein expression increases cellular organ-
ismal sensitivity to rotenone, a mitochondrial complex I
inhibitor [78,158]. Furthermore, intact mitochondrial
function is required for a-synuclein toxicity in a yeast
model, although it should also be noted that removal of
mitochondria is also quite damaging in the same contextMolecular Neurodegeneration 2009, 4:9 http://www.molecularneurodegeneration.com/content/4/1/9
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[57]. The mechanism by which α-synuclein interacts with
and causes damage to mitochondria is not fully resolved
and, given the central role of mitochondria in apoptotic
pathways, perhaps such effects are secondary to the induc-
tion of apoptosis. Increased levels of α-synuclein are
reported to trigger apoptosis in various cell types [159-
161]. Several apoptotic markers are also seen in yeast
models of synuclein toxicity [59]. α-Synuclein toxicity can
be rescued by caspase inhibitors or knock down of cas-
pase-12 [87]. Activation of caspase-3 has been reported in
transgenic mice [162] caspase-9 has been reported in viral
models in mice [102] and rats [106]. However, these stud-
ies show only a few caspase positive cells, and so whether
apoptosis is the only way in which cells expressing α-
synuclein die remains unclear.
α-Synuclein can bind to the membranes of lysosomes
[135] and inhibit lysosomal function [163] and chaper-
one-mediated autophagy [135]. Recent results suggest
that CMA is implicated in the regulation of the transcrip-
tion factor MEF2D and that this can be disrupted by
expression of α-synuclein, leading to neuronal death
[164]. As another example of misregulated protein turno-
ver, α-synuclein (and specifically α-synuclein oligomers)
can also inhibit the proteasome [81,88,163,165-167],
although it is not clear if the predicted altered turnover of
proteasome substrates occurs in vivo [168].
The general principle is that multiple systems can be
affected by α-synuclein expression and that if there is a
common theme between them, it is likely to be that α-
synuclein can binds lipids. Several lines of evidence sug-
gest that lipid binding can promote the formation of oli-
gomers [115,145,169]. Therefore, this interpretation links
a primary protein abnormality to cellular targets of the
protein. As discussed elsewhere [144], determining which
events are truly primary and which are secondary remains
a challenge. Although this distinction is an intellectual
problem, it may also be relevant for deciding which
aspects of cell death to target if we want to limit the dis-
ease process in PD.
Potential therapeutic approaches related to α-
synuclein toxicity
One of the key questions here is to decide whether to try
and target the protein or the process that mediates cellular
damage. Both are attractive for different reasons, although
both are also difficult (see figure 1 for where these might
be utilized and Appendix 2 for the critical next steps).
If there were a pathogenic aggregated form of α-synuclein,
then one tactic would be to target that species. If we pro-
pose that insoluble fibrils are toxic, then a 'fibril-buster'
would be the way forward [reviewed in [111]], but if sol-
uble oligomers damage cells then we would want to pre-
vent their formation or encourage their turnover. As
discussed above, both fibrils and oligomers can be found
in different models and either alone, or both, could be
toxic. For oligomers, the situation is more complicated if
different oligomeric forms have different toxic properties
[118], suggesting that we may need to be careful about
which oligomers we target.
Alternatively, we could be agnostic about which species
are important and try and decrease all α-synuclein expres-
sion. There are reports that increasing autophagy can help
clear aggregation-prone proteins, including α-synuclein
[170]. Antisense approaches might also be helpful, and
have been reported to work in the rat [171] and mouse
[172] brain. This approach is predicated on the idea that
α-synuclein really is dispensable for CNS function in
humans, as it appears to be in the mouse [28,30], but per-
haps even a modest decrease in protein levels would be
enough to decrease PD progression.
We might also try to change the modifications of α-synu-
clein, especially if these are specific for pathogenic forms.
For example, example of PLK2 as a kinase for Ser129 [127]
may provide a way to test the idea that phosphorylation at
this residue is key for pathogenesis, if sufficiently specific
kinase inhibitors can be developed. Again, assuming spe-
cificity can be achieved, it might be interesting to block
other modifications such as truncation or nitrosylation –
the latter might be part of the general rubric of anti-
inflammatory approaches. However, such approaches
would only be helpful if the modification is truly specific
for the pathogenic form and makes an active contribution
to cellular toxicity, ie is not a bystander in the process.
Finally, we may target one or more of the cellular effects
of α-synuclein that are associated with toxicity. This might
have the advantage of leaving the protein alone, which
may be useful if it turns out that α-synuclein has a specific
function in the human brain. The difficulty, of course, is
in understanding why the protein is toxic, although the
work with Rab1 [151,173] suggests that this is a tractable
problem, at least in principle.
Conclusion
Cell death is a significant part of the pathology of PD.
Although the process is a mysterious, the prime suspect
for a toxic protein is α-synuclein. Assuming toxicity does
indeed result from aberrant forms of the protein, includ-
ing increased expression of the normal gene, there are two
major aspects that might be targeted therapeutically. First,
the protein is prone to aggregate and anti-aggregative
compounds, or approaches to simply limit net expression
levels, may be helpful. Second, there are a number of
molecular events that largely revolve around membrane
or organelle interactions that may contribute to toxicity,
and these too may be targeted therapeutically. Future
work should be directed at exploring these possibilities asMolecular Neurodegeneration 2009, 4:9 http://www.molecularneurodegeneration.com/content/4/1/9
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well as at developing models that have a stronger cell
death signal, to more accurately represent the substantive
loss of neurons seen in PD.
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Appendix 1: key observations
The role of α-synuclein in PD and related disease is high-
lighted by the convergence of pathological and genetic
data. Because part of the pathological phenotype of PD
involves cell death of neurons, particularly but not exclu-
sively dopamine neurons in the substantia nigra pars
compacta, this suggests that α-synuclein may be a toxic
protein. The following key observations have been made
in various experimental systems to support this conten-
tion:
- In pure in vitro assays, α-synuclein shows a lack of con-
formational restraint that tends to promote inappropriate
aggregation. This can be enhanced by mutation, increas-
ing concentration or any of several protein modifications
associated with pathological deposition of the protein in
vivo. α-Synuclein can also bind lipids and membranes in
vitro
- In a variety of species, expression of α-synuclein can pro-
mote toxic events. These include organisms such as yeast,
worms and flies, where no α-synuclein homologue is
present, suggesting that irrespective of its normal func-
tion, the protein can be toxic.
- Data in mammalian cell culture also supports a toxic
effect of α-synuclein, particularly to dopaminergic cells.
Results in intact in vivo systems are mixed, with toxicity
limited to the spinal cord in some transgenic mouse mod-
els and modest toxic effects to dopaminergic neurons
using viral mediated overexpression in rodents and non-
human primates.
- The mechanism(s) involved are currently unclear, but
binding to several cellular membranes may contribute to
toxic events.
Appendix 2: critical next steps
The following critical issues need to be addressed before
our understanding of α-synuclein pathobiology can be
applied to therapeutic development:
- We need to better understand normal function of α-
synuclein, such that we can assess both what role it might
play in toxicity in the mammalian CNS and so we can
highlight potential detrimental effects of limiting expres-
sion or function of the protein.
- We need to clearly identify which cellular pathways con-
tribute to the pathological effects of the protein. Some
great work has been performed in yeast models that high-
light interruption of vesicle transport, but it is important
now to establish what the analogous process is in neurons
and whether this is sufficient to explain α-synuclein toxic-
ity in this system.
- We need to develop models where there is a lesion that
better approximates the severity of cell loss seen in human
PD. This will allow for a more rigorous test of pathways
involved in toxicity as the disease progresses. An acceler-
ated time course would be helpful, and may be necessary,
but the pathology should be similar to human PD in that
nigral neurons should be affected at some point in the
model but not necessarily first or exclusively.
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